Achieving and maintaining long-term optimal improvements in patient-reported symptoms, signs, and quality of life among patients with moderate-to-severe psoriasis treated with guselkumab: 5-year data from VOYAGE 1

被引：0
|
作者：
Griffiths, Christopher E. M. [1 ]
Blauvelt, Andrew [2 ]
Han, Chenglong [3 ]
Fernandez-Penas, Pablo [4 ,5 ]
Adam, David N. [6 ,7 ]
Philipp, Sandra [8 ]
Song, Michael [9 ]
Miller, Megan [9 ]
You, Yin [9 ]
Langley, Richard G. [10 ]
机构：
[1] Univ Manchester, Salford Royal NHS Fdn Trust, NIHR Manchester Biomed Res Ctr, Dermatol Ctr, Manchester, Lancs, England
[2] Oregon Med Res Ctr, Portland, OR USA
[3] Janssen Global Serv LLC, Raritan, NJ USA
[4] Univ Sydney, Sydney, NSW, Australia
[5] Westmead Hosp, Westmead, NSW, Australia
[6] CCA Med Res Corp & Probity Med Res, Ajax, ON, Canada
[7] Prob Med Res, Waterloo, ON, Canada
[8] Charite Univ Med Berlin, Dept Dermatol, Berlin, Germany
[9] Janssen Res & Dev LLC, Raritan, NJ USA
[10] Dalhousie Univ, Halifax, NS, Canada
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2021年 / 85卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
27043
引用
收藏
页码：AB127 / AB127
页数：1
相关论文
共 50 条
  • [11] Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes
    Cork, M. J.
    McMichael, A.
    Teng, J.
    Valdez, H.
    Rojo, R.
    Chan, G.
    Zhang, F.
    Myers, D. E.
    DiBonaventura, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (03) : 422 - 433
  • [12] Achieving long-term sustained response is associated with improvements In patient-reported outcomes in patients with psoriasis treated with ABT-874
    Papp, Kim
    Yu, Andrew
    Sundaram, Murali
    Bao, Yanjun
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : AB160 - AB160
  • [13] Effect of Ixekizumab on Patient Reported Outcomes and Quality of Life in Patients With Moderate-to-Severe Plaque Psoriasis: 5-Year Results from the UNCOVER-1 and-2 Studies
    Gooderham, Melinda J.
    Elewski, Boni
    Augustin, Matthias
    Iversen, Lars
    Torii, Hideshi
    Burge, Russel
    See, Kyoungah
    Gallo, Gaia
    Eastman, William J.
    McKean-Matthews, Missy
    Foley, Peter
    JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (04) : 394 - 401
  • [14] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [15] Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1
    Strober, Bruce
    Gordon, Kenneth
    Augustin, Matthias
    Viswanathan, Hema
    Klekotka, Paul
    Milmont, Cassandra
    Kricorian, Gregory
    Harrison, David
    Pinto, Lionel
    Nirula, Ajay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB256 - AB256
  • [16] Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trial
    Costanzo, Antonio
    Conrad, Curdin
    Gramiccia, Talia
    Jazra, Maria
    de Jong, Elke M. G. J.
    Iversen, Lars
    Ozturk, Bulent
    Wapenaar, Robert
    Wegner, Sven
    Torres, Tiago
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
  • [17] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Mark G. Lebwohl
    Andrew Blauvelt
    Alan Menter
    Kim A. Papp
    Scott Guenthner
    Radhakrishnan Pillai
    Robert J. Israel
    Abby Jacobson
    American Journal of Clinical Dermatology, 2019, 20 : 863 - 871
  • [18] Efficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study
    Lebwohl, Mark G.
    Blauvelt, Andrew
    Menter, Alan
    Papp, Kim A.
    Guenthner, Scott
    Pillai, Radhakrishnan
    Israel, Robert J.
    Jacobson, Abby
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2019, 20 (06) : 863 - 871
  • [19] Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Lebwohl, Mark
    Langley, Richard G.
    Rowland, Katelyn
    Yang, Ya-Wen
    Chan, Daphne
    Miller, Megan
    You, Yin
    Yu, Jenny
    Thaci, Diamant
    Foley, Peter
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 274 - 282
  • [20] Guselkumab therapy improves patient-reported signs, symptoms and health-related quality of life of patients with moderate-severe psoriasis with inadequate response to ustekinumab: Results from phase III NAVIGATE study
    Langley, Richard G.
    Tsai, Tsen-Fang
    Han, Chenglong
    Flavin, Susan
    Song, Michael
    Randazzo, Bruce
    Jiang, Jingzhi
    Li, Shu
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB150 - AB150
12345